poisar

Stocks · News reference

Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PEN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Reasons to Retain Penumbra Stock in Your Portfolio for Now

    Penumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.

    PENVCYTGMEDTFX
  3. Na

    Incuvate Files Patent Infringement Lawsuit Against Penumbra

    Incuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.

    PEN